Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU1-40P (RNA, U1 small nuclear 40, pseudogene) is a human pseudogene related to the U1 small nuclear RNA family[1][5]. U1 small nuclear RNAs (snRNAs) are essential components of the spliceosome involved in pre-mRNA splicing and are highly conserved non-coding RNAs[2][3]. However, RNU1-40P itself is designated as a pseudogene, meaning it is a genomic sequence similar to functional genes, but it carries mutations, deletions, or sequence variations that prevent it from encoding a functional RNA molecule. Although some U1-related pseudogenes (called “variant U1 snRNAs”) have recently been shown to be transcribed and may regulate mRNA processing in general, there is no specific evidence for RNU1-40P being either transcribed or functional[2]. Most U1 snRNA pseudogenes, including RNU1-40P, are considered nonfunctional segments of DNA retained in the genome with no established biological activity[2]. RNU1-40P is not considered a validated or potential therapeutic target (receptor, enzyme, transporter, etc.), and there is no evidence supporting its involvement in any pharmacological mechanism, disease process, drug interaction, or use as a biomarker[1][5].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 40, pseudogene (RNU1-40P).